Contents

Drug competition: The Waxman-Hatch Act revisited

Virabhak, Suchin / Sohn, Wook

  • 0 WEB OF SCIENCE
  • 1 SCOPUS
  • 182 ITEM VIEW
  • 0 DOWNLOAD
Abstract

This paper examines generic competition following the enactment of the 1984Waxman-Hatch Act. Unlike the existing literature, we employ antibiotics as a control group to infer legislation-induced increases in generic competition. Using FDA drug approval data, we find evidence that the Act enhanced generic competition, resulting in 1.5 times more competition between nonantibiotic drugs than between antibiotics. Moreover, the Act's overall impact is greater for newer drugs than older drugs. Copyright © by The Haworth Press, Inc. All rights reserved.

Issue Date
2007
Publisher
Haworth Press Inc.
Keywords
antibiotic agent; generic drug; non prescription drug; trichlormethiazide; drug approval; drug competition; drug cost; drug efficacy; drug industry; drug manufacture; drug marketing; drug safety; expiration date; food and drug administration; law; policy; priority journal; review
Citation
JOURNAL OF PHARMACEUTICAL FINANCE, ECONOMICS AND POLICY, v.15, no.2, pp.3 - 20, 2007
DOI
10.1300/J371v15n02_02
Journal Title
JOURNAL OF PHARMACEUTICAL FINANCE, ECONOMICS AND POLICY
Start Page
3
End Page
20
ISSN
1538-5698
Language
English
Files in This Item:
    There are no files associated with this item.

Click the button and follow the links to connect to the full text. (KDI CL members only)

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.